Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:
“FDA approves subcutaneous amivantamab – finally!
This is a no-brainer switch in my opinion. Faster, decrease risk of infusion reaction, less risk of VTE. Even possibility of greater efficacy versus IV (needs confirmation). Will switch as soon as we can.”
Read the full press release.
More posts featuring Stephen Liu on OncoDaily.